<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="83160">
  <stage>Registered</stage>
  <submitdate>15/09/2008</submitdate>
  <approvaldate>7/11/2008</approvaldate>
  <actrnumber>ACTRN12608000562370</actrnumber>
  <trial_identification>
    <studytitle>The effects of exogenous glucagon-like peptide-1 administration on glucose metabolism and gastric emptying in critically ill patients.</studytitle>
    <scientifictitle>Double-blind randomised placebo cross-over trial of exogenous glucagon-like peptide-1 to establish the effect on glucose metabolism and gastric emptying during gastric feeding in critically ill patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>There is no secondary ID</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Critical illness</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intravenous Glucagon-like peptide-1 (reconstituted in 4%albumin) at 1.2pmol/kg/min will be administered for 360minutes at 1ml/min.  Seperated by 24 hours the cross-over treatment is placebo (intravenous 4% Albumin at 1ml/min for 360minutes</interventions>
    <comparator>placebo (4% albumin solution intravenous for 360minutes at 1ml/min)</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>blood glucose concentration.  Measured using bedside glucometer</outcome>
      <timepoint>0-6 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>gastric emptying.  Measured using scintigraphic and breath test techniques</outcome>
      <timepoint>0-8 hours</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>nutrient absorption.  Measured using absorption of 3-O-Methyl-Glucose.</outcome>
      <timepoint>0-4 hours</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Regulatory and counter-regulatory hormone release.  Measured using plasma Insulin and glucagon concentrations</outcome>
      <timepoint>0-6 hours</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>plasma GLP-1 concentration</outcome>
      <timepoint>0-6 hours</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>critically ill patients and mechanically ventilated suitable for, or receiving, enteral nutrition and likely to stay ventilated for at least 48 hours.</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy, Contraindication to enteral nutrient administration, Previous surgery on the oesophagus, stomach or duodenum, Any gastrointestinal surgery on this hospital admission and History of diabetes mellitus</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Cross-over study.  Randomisation is performed by the pharmacy department of the Royal Adelaide Hospital using statistical software.  Once the peptide is reconstituted the study drug or placebo is packaged and labelled study drug.  The investigator will  receive the study drug from the pharmacy department and have no involvement in preparation of solution or randomisation schedule.</concealment>
    <sequence>computer generated</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>31/10/2008</anticipatedstartdate>
    <actualstartdate>4/11/2008</actualstartdate>
    <anticipatedenddate>31/10/2013</anticipatedenddate>
    <actualenddate>27/07/2009</actualenddate>
    <samplesize>25</samplesize>
    <actualsamplesize>25</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Adelaide Hospital Intensive Care Unit</primarysponsorname>
    <primarysponsoraddress>Floor 4
Royal Adelaide Hospital
North Terrace
Adelaide
5000 SA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC)</fundingname>
      <fundingaddress>Level 5, 20 Allara Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>adam deane</sponsorname>
      <sponsoraddress>Floor 4
Royal Adelaide Hospital
North Terrace
Adelaide 5000
SA</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adequate nutrition is important to allow patients in the Intensive Care Unit the best chance to recover from their illness. The most common method of feeding patients is through a tube into the gut. However, due to their illness many of these patients have very high levels of glucose (sugar) in the bloodstream, which can have a negative effect on their recovery.   The purpose of this study is to determine whether a naturally occurring hormone, called Glucagon-like Peptide-1 (GLP-1), can help lower blood glucose levels and improve the outcome of patients in Intensive Care. GLP-1 is a gastrointestinal hormone that is normally released into the bloodstream in response to a meal.</summary>
    <trialwebsite />
    <publication>Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M. Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med. 2010 May;38(5):1261-9.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress>IMVS Building
Royal Adelaide Hospital 
North Terrace
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>1/07/2008</ethicapprovaldate>
      <hrec>061229 V3</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital Research Ethics Committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/07/2008</ethicapprovaldate>
      <hrec>061229c</hrec>
      <ethicsubmitdate />
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>adam deane</name>
      <address>Intensive Care Unit
Floor 4
Royal Adelaide Hospital
North Terrace
Adelaide
SA 
5000</address>
      <phone>08 8222-4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane</name>
      <address>Intensive Care Unit
Floor 4
Royal Adelaide Hospital
North Terrace
Adelaide SA
5000</address>
      <phone>08 8222-4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>adam deane</name>
      <address>Intensive Care Unit
Floor 4
Royal Adelaide Hospital
North Terrace
Adelaide
SA
5000</address>
      <phone>08 8222-4000</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Adam Deane </name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide 
SA 5000</address>
      <phone>+618 8222 2818</phone>
      <fax />
      <email>adam.deane@adelaide.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>